Skip to main content
Erschienen in: Pediatric Cardiology 4/2014

01.04.2014 | Original Article

Perventricular Closure of Perimembranous Ventricular Septal Defects Using the Concentric Occluder Device

verfasst von: Shunmin Wang, Zhongyun Zhuang, Haibo Zhang, Jinhao Zhen, Yanan Lu, Jinfen Liu, Zhiwei Xu

Erschienen in: Pediatric Cardiology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

This report summarizes the authors’ clinical experience with perventricular closure of the perimembranous ventricular septal defect (PmVSD) using the concentric occluder as a minimally invasive technique without cardiopulmonary bypass and following transesophageal echocardiography (TEE) guidance. Between July 2011 and March 2013, 61 patients with PmVSD underwent perventricular concentric device closure using a minimally invasive inferior sternotomy approach. The basal diameter of the PmVSD ranged from 2.5 to 7 mm. The diameter of the occlusion device waist ranged from 4 to 8 mm. A ventricular septal aneurysm or an adhesive tricuspid valve was present in 49 patients. Multiple orifices in the aneurysm were treated in ten patients, including dispersed orifices in four patients and comparatively concentrated orifices in the remaining six patients. The occlusion devices were deployed via the right ventricle with TEE guidance and no cardiopulmonary bypass. Complete shunt occlusion was achieved for all the patients in the operating room. The orifices of the ventricular septal aneurysm were closed in 46 patients, with the left disc of the concentric devices placed in the aneurysms, whereas the PmVSDs in the remaining 15 patients were closed from the ventricular septal defect (VSD) basal part following the rule that the upper rim of the PmVSD be more than 2 mm from the aortic valve. Ventricular premature beats occurred in one patient. The follow-up period ranged from 1 to 21 months (median 13.5 ± 8.2 months), and the patients had stable heart function postoperatively. None of the patients had more than mild valvular regurgitation, and no worsening regurgitation was observed in those who had tricuspid or aortic regurgitation before surgery. No complete atrioventricular block, position shift of the occlusion devices, thrombosis, or residual VSD occurred during the follow-up period. The perventricular concentric device closure of PmVSD with an inferior sternotomy in selected patients is a safe, feasible, and simple treatment. The concentric device is easier to anchor than the eccentric device and has proved to be a reasonable choice for PmVSD occlusion, especially in patients with a perimembranous aneurysm formation or PmVSD extending to the inflow tract.
Literatur
1.
Zurück zum Zitat Butera G, Carminati M, Chessa M et al (2007) Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol 50:1189–1195CrossRefPubMed Butera G, Carminati M, Chessa M et al (2007) Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol 50:1189–1195CrossRefPubMed
2.
Zurück zum Zitat Cao H, Chen Q, Zhang GC et al (2011) Intraoperative device closure of perimembranous ventricular septal defects in the young children under transthoracic echocardiographic guidance: initial experience. J Cardiothorac Surg 6:166–172PubMedCentralCrossRefPubMed Cao H, Chen Q, Zhang GC et al (2011) Intraoperative device closure of perimembranous ventricular septal defects in the young children under transthoracic echocardiographic guidance: initial experience. J Cardiothorac Surg 6:166–172PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Fu YC, Bass J, Amin Z et al (2006) Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder results of the U.S. phase I trial. J Am Coll Cardiol 47:319–325CrossRefPubMed Fu YC, Bass J, Amin Z et al (2006) Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder results of the U.S. phase I trial. J Am Coll Cardiol 47:319–325CrossRefPubMed
4.
Zurück zum Zitat Hijazi ZM, Hakim F, Haweleh AA et al (2002) Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD coccluder: initial clinical experience. Catheter Cardiovasc Interv 56:508–515CrossRefPubMed Hijazi ZM, Hakim F, Haweleh AA et al (2002) Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD coccluder: initial clinical experience. Catheter Cardiovasc Interv 56:508–515CrossRefPubMed
5.
Zurück zum Zitat Holzer R, Jd Giovanni, Walsh KP et al (2006) Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer membranous VSD occluder: immediate and midterm results of an international registry. Catheter Cardiovasc Interv 68:620–628CrossRefPubMed Holzer R, Jd Giovanni, Walsh KP et al (2006) Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer membranous VSD occluder: immediate and midterm results of an international registry. Catheter Cardiovasc Interv 68:620–628CrossRefPubMed
6.
Zurück zum Zitat Masura J, Gao W, Gavora P et al (2005) Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol 26:216–219CrossRefPubMed Masura J, Gao W, Gavora P et al (2005) Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol 26:216–219CrossRefPubMed
7.
Zurück zum Zitat Ovaert C, Dragulescu A, Sluysmans T et al (2008) Early surgical removal of membranous ventricular septal device might allow recovery of atrioventricular block. Pediatr Cardiol 29:971–975CrossRefPubMed Ovaert C, Dragulescu A, Sluysmans T et al (2008) Early surgical removal of membranous ventricular septal device might allow recovery of atrioventricular block. Pediatr Cardiol 29:971–975CrossRefPubMed
8.
Zurück zum Zitat Pedra CAC, Pedra SRF, Esteves CA et al (2004) Percutaneous closure of perimembranous ventricular septal defects with the Amplatzer device: technical and morphological considerations. Catheter Cardiovasc Interv 61:403–410CrossRefPubMed Pedra CAC, Pedra SRF, Esteves CA et al (2004) Percutaneous closure of perimembranous ventricular septal defects with the Amplatzer device: technical and morphological considerations. Catheter Cardiovasc Interv 61:403–410CrossRefPubMed
9.
Zurück zum Zitat Predescu D, Chaturvedi RR, Friedberg MK et al (2008) Complete heart block associated with device closure of perimembranous ventricular septal defects. J Thorac Cardiovasc Surg 136:1223–1228CrossRefPubMed Predescu D, Chaturvedi RR, Friedberg MK et al (2008) Complete heart block associated with device closure of perimembranous ventricular septal defects. J Thorac Cardiovasc Surg 136:1223–1228CrossRefPubMed
10.
Zurück zum Zitat Tao K, Lin K, Shi Yk et al (2010) Perventricular device closure of perimembranous ventricular septal defects in 61 young children: early and midterm follow-up results. J Thorac Cardiovasc Surg 140:864–870CrossRefPubMed Tao K, Lin K, Shi Yk et al (2010) Perventricular device closure of perimembranous ventricular septal defects in 61 young children: early and midterm follow-up results. J Thorac Cardiovasc Surg 140:864–870CrossRefPubMed
11.
Zurück zum Zitat Walsh MA, Bialkowski J, Szkutnik M et al (2006) Atrioventricular block after transcatheter closure of perimembranous ventricular septal defects. Heart 92:1295–1297PubMedCentralCrossRefPubMed Walsh MA, Bialkowski J, Szkutnik M et al (2006) Atrioventricular block after transcatheter closure of perimembranous ventricular septal defects. Heart 92:1295–1297PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Wang L, Cao SC, Li J et al (2012) Perimembranous ventricular septal defect in children using symmetric occluders: an 8-year multi-institutional experience. Ann Thorac Surg 94:592–598CrossRefPubMed Wang L, Cao SC, Li J et al (2012) Perimembranous ventricular septal defect in children using symmetric occluders: an 8-year multi-institutional experience. Ann Thorac Surg 94:592–598CrossRefPubMed
13.
Zurück zum Zitat William CLY, Frank Z, Hijazi ZM et al (2005) Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect. Catheter Cardiovasc Interv 66:436–441CrossRef William CLY, Frank Z, Hijazi ZM et al (2005) Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect. Catheter Cardiovasc Interv 66:436–441CrossRef
14.
Zurück zum Zitat Xing QS, Pan S, Zhuang ZY et al (2009) Minimally invasive perventricular device closure of an isolated perimembranous ventricular septal defect with a newly designed delivery system: preliminary experience. J Thorac Cardiovasc Surg 137:556–559CrossRef Xing QS, Pan S, Zhuang ZY et al (2009) Minimally invasive perventricular device closure of an isolated perimembranous ventricular septal defect with a newly designed delivery system: preliminary experience. J Thorac Cardiovasc Surg 137:556–559CrossRef
15.
Zurück zum Zitat Xing QS, Pan S, Qi A et al (2010) Minimally invasive perventricular device closure of perimembranous ventricular septal defect without cardiopulmonary bypass: multicenter experience and midterm follow-up. J Thorac Cardiovasc Surg 139:1409–1415CrossRefPubMed Xing QS, Pan S, Qi A et al (2010) Minimally invasive perventricular device closure of perimembranous ventricular septal defect without cardiopulmonary bypass: multicenter experience and midterm follow-up. J Thorac Cardiovasc Surg 139:1409–1415CrossRefPubMed
Metadaten
Titel
Perventricular Closure of Perimembranous Ventricular Septal Defects Using the Concentric Occluder Device
verfasst von
Shunmin Wang
Zhongyun Zhuang
Haibo Zhang
Jinhao Zhen
Yanan Lu
Jinfen Liu
Zhiwei Xu
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 4/2014
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-013-0823-0

Weitere Artikel der Ausgabe 4/2014

Pediatric Cardiology 4/2014 Zur Ausgabe

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.